XT
ACET icon

XTX Topco’s Adicet Bio ACET Stock Holding History

XTX Topco’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
24,284
+5,158
+27% +$40.6K ﹤0.01% 3218
2026
Q1 		$130K Buy
19,126
+516
+3% +$3.86K ﹤0.01% 3014
2025
Q4 		$157K Buy
18,610
+14,976
+412% +$166K ﹤0.01% 2485
2025
Q3 		$47.1K Buy
3,634
+2,160
+147% +$25.4K ﹤0.01% 2185
2025
Q2 		$14.4K Buy
+1,474
New +$15.5K ﹤0.01% 2209
2025
Q1 		– Sell
-4,262
Closed -$65.6K – 2336
2024
Q4 		$65.6K Sell
4,262
-13,999
-77% -$264K 0.01% 1851
2024
Q3 		$421K Buy
18,261
+2,024
+12% +$45.3K 0.03% 938
2024
Q2 		$314K Buy
16,237
+2,109
+15% +$56.5K 0.03% 927
2024
Q1 		$531K Buy
14,128
+12,690
+882% +$525K 0.07% 451
2023
Q4 		$43.5K Sell
1,438
-2,038
-59% -$44.4K 0.01% 1252
2023
Q3 		$76.2K Buy
3,476
+841
+32% +$29.7K 0.01% 1218
2023
Q2 		$102K Buy
2,635
+1,940
+279% +$171K 0.02% 1160
2023
Q1 		$64K Sell
695
-1,143
-62% -$143K 0.01% 1146
2022
Q4 		$263K Buy
+1,838
New +$459K 0.06% 682

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

XTX Topco's ACET Position: Q2 2026 in Review

XTX Topco increased its Adicet Bio (ACET) stake by 27% in Q2 2026, buying an estimated $40.6K and bringing the position to 24,284 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #3218.

XTX Topco first reported a position in ACET in Q4 2022 and has held it in 14 quarters since. The position peaked at $531K in Q1 2024. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • XTX Topco held 24,284 shares of Adicet Bio worth $210K as of Q2 2026.
  • XTX Topco bought 5,158 Adicet Bio shares in Q2 2026, an estimated $40.6K.
  • Adicet Bio made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3218 holding.
  • XTX Topco first reported a position in Adicet Bio in Q4 2022 and has held it in 14 quarters since.
  • XTX Topco's Adicet Bio position peaked at $531K in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.